Patents Assigned to CollaGenex Pharmaceuticals, Inc.
  • Patent number: 7232572
    Abstract: A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: June 19, 2007
    Assignee: CollaGenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Patent number: 7211267
    Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: May 1, 2007
    Assignee: CollaGenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Patent number: 7014858
    Abstract: A method of treating telangiectasia in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat telangiectasia, but has substantially no antibiotic activity.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: March 21, 2006
    Assignee: CollaGenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Patent number: 7008631
    Abstract: A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: March 7, 2006
    Assignee: CollaGenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Patent number: 6946453
    Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: September 20, 2005
    Assignee: CollaGenex Pharmaceuticals, Inc.
    Inventors: Robert A. Ashley, Joseph J. Hlavaka
  • Publication number: 20040147492
    Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
    Type: Application
    Filed: January 14, 2004
    Publication date: July 29, 2004
    Applicant: CollaGenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Publication number: 20040002481
    Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N-NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.
    Type: Application
    Filed: June 10, 2003
    Publication date: January 1, 2004
    Applicant: CollaGenex Pharmaceuticals, Inc.
    Inventors: Robert Ashley, Joseph J. Hlavka
  • Patent number: 5827503
    Abstract: Oral hygiene is improved and diseases of the oral cavity are treated by oral application of a composition containing 0.02 to 0.25 weight percent alkyldimethylbenzylammonium chloride (BAC) and 0.05 to 2.0 weight percent sodium chloride dissolved in water, in the absence of other active ingredients. The BAC and sodium chloride act synergistically to allow the composition to sorb strongly to oral tissues and remain there for several hours.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: October 27, 1998
    Assignee: Collagenex Pharmaceuticals, Inc.
    Inventor: Christian Schwabe
  • Patent number: 5792446
    Abstract: A delivery system for controlled administration of a dentin-hypersensitivity-ameliorating composition to targeted areas is described. In particular, a bio-compatible delivery vehicle is described which contains unreacted, reactive materials dispersed therein. These materials form a dentin-hypersensitivity-ameliorating composition when reacted. Furthermore, these materials are separately encapsulated within protective encapsulating matrices to prevent the reaction thereof until delivery of the materials to a dentinal surface.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: August 11, 1998
    Assignee: Collagenex Pharmaceuticals, Inc.
    Inventor: Robert A. Ashley
  • Patent number: 5753711
    Abstract: In a method for preventing the spread of Helicobacter pylori from the oral cavity, the oral cavity is contacted with alkyldimethylammonium chloride. The contacting is advantageously used in conjunction with enteric antimicrobial therapy for H. pylori or for prophylaxis thereof.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: May 19, 1998
    Assignee: Collagenex Pharmaceuticals, Inc.
    Inventors: Christian Schwabe, Robert A. Ashley